Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus, a drug delivery company, has named Jan Hendrik Egberts as chief executive officer (CEO).
Subscribe to our email newsletter
Egberts will replace current CEO Simon Sturge, who will leave the company as per 1 January 2011.
Egberts is expected to immediately start working together with Sturge until the end of this year to ensure a smooth transition.
Egberts worked for four years as a strategic consultant to life sciences companies at McKinsey & Company, and from 1994 onwards held business development and general management positions of increasing responsibility in the US at Merck, Johnson & Johnson and Molnlycke Health Care.
Egberts became CEO of Novadel Pharmaceuticals in 2005 and subsequently, he has served as senior advisor in healthcare investments to private equity firm 3i Group.
Egberts said that OctoPlus is making progress in commercialising its controlled release technology.
OctoPlus board of supervisory directors chairman Hans Stellingsma said that the board of supervisory directors is proud to have recruited Jan Hendrik Egberts as CEO.
"He is an experienced professional and we look forward to welcoming him to the executive team," Stellingsma said.
"The Board nominates Egberts based on his successful track record in general management, investment management and business development."